Combined Pain Neuroscience Education and Progressive Muscle Relaxation for Post-Thoracoscopic Pain.

Pain Manag NursMay 5, 2026 (epub)
Clinical ResearchAnesthesiology

Xueqin Wang, Wenyan Li, Fan Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of combining pain neuroscience education (PNE) with progressive muscle relaxation (PMR) on postoperative pain in 58 patients after thoracoscopic lung resection. The study found that the experimental group experienced lower postoperative pain and reduced central sensitization and pain catastrophizing compared to the control group.

Key findings

  • Patients receiving PNE + PMR reported lower postoperative pain intensity compared to controls.
  • The experimental group showed reduced central sensitization and pain catastrophizing.
  • Less frequent use of rescue analgesics was noted in the PNE + PMR group.

Why it matters

Understanding non-pharmacological strategies like PNE and PMR can help clinicians enhance pain management protocols, potentially improving patient outcomes and reducing opioid reliance in postoperative care.

Source

PubMed · PMID 42086442

Published in Pain Manag Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Anesthesiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.